Breakaway

Breakaway Biosciences is a biotechnology company focused on developing a rapid, phenotypic antimicrobial susceptibility testing (AST) platform designed to transform the management of sepsis and other life-threatening infections. By utilizing single-cell analysis and microfluidics, the company's technology aims to provide clinicians with actionable results in hours rather than days, enabling faster administration of targeted antibiotic therapy. This approach addresses the critical need for timely diagnostics in the face of rising antimicrobial resistance. The company's platform is intended to reduce hospital stays, lower healthcare costs, and significantly improve patient outcomes in acute care settings.